SCHEMBL15575381

SCHEMBL15575381

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3ccc(C)cc3CO)cc2C)ccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 4/20 0.71
L3MBTL1 Q9Y468 1/20 0.44
CARM1 Q86X55 2/20 0.42
PRMT6 Q96LA8 2/20 0.42
RAF1 P04049 4/20 0.42
KDR P35968 3/20 0.41
ABL1 P00519 2/20 0.41
MAPK14 Q16539 2/20 0.41
CSF1R P07333 1/20 0.41
KMT2A Q03164 1/20 0.41
RIPK2 O43353 2/20 0.40
EPHX2 P34913 3/20 0.40
P2RX3 P56373 2/20 0.39
ABCB11 O95342 1/20 0.39
NR3C1 P04150 1/20 0.39
RET P07949 1/20 0.39
HTR1A P08908 1/20 0.39
PDGFRB P09619 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15573135 0.91 DDR2 (0.71) DDR2CARM1PRMT6RAF1KDR
SCHEMBL16990660 0.91 DDR2 (0.58) DDR2L3MBTL1CARM1PRMT6KDR
SCHEMBL17000027 0.90 DDR2 (0.84) DDR2L3MBTL1RAF1CSF1RKMT2A
SCHEMBL15574614 0.87 DDR2 (0.68) DDR2CARM1PRMT6RAF1KDR
SCHEMBL15574704 0.86 DDR2 (0.69) DDR2L3MBTL1CARM1PRMT6RAF1
SCHEMBL15574157 0.86 DDR2 (0.69) DDR2L3MBTL1CARM1PRMT6RAF1
SCHEMBL15574754 0.86 DDR2 (0.51) DDR2L3MBTL1CARM1PRMT6MAPK14
SCHEMBL15574423 0.86 DDR2 (0.68) DDR2CARM1PRMT6RAF1KDR
SCHEMBL17000078 0.85 DDR2 (0.82) DDR2L3MBTL1RAF1KDRMAPK14
SCHEMBL15573230 0.84 DDR2 (0.73) DDR2CARM1PRMT6RAF1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885L3MBTL1 3554/4885CARM1 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.